--- title: "Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG" type: "News" locale: "en" url: "https://longbridge.com/en/news/295902995.md" description: "Biotech and healthcare stocks PARK, AVAH, CADL, LH, and COAG reached 52-week highs on August 13, 2026, driven by positive Q2 earnings and increased guidance. Park Dental Partners (PARK) rose 10% with 5.1% revenue growth. Labcorp (LH) hit a high of $325.58 amid 5.8% revenue growth. Aveanna Healthcare (AVAH) surged 24% with 13.7% revenue growth. Candel Therapeutics (CADL) climbed 10% despite higher net losses due to warrant liabilities. Hemab Therapeutics (COAG) reached a high of $55.18 following positive Phase 2 trial data for its blood disorder therapies." datetime: "2026-08-14T08:26:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295902995.md) - [en](https://longbridge.com/en/news/295902995.md) - [zh-HK](https://longbridge.com/zh-HK/news/295902995.md) --- # Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG Add as your preferred news source on Google Add Now The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures. **Park Dental Partners (PARK)** Park Dental is a dental resource management organization that provides business support services to clinical team members, administrative personnel, facilities and equipment to general and multi-speciality dental practices. The company saw shares rise to a 52-week high of $26.79, closing the day up 10%. On Tuesday, the company announced second quarter earnings reflecting a revenue growth of 5.1% from $63 million in the previous year to $66.2 million in 2026. The company anticipates a consistent full year revenue growth of 5.5% in 2026, potentially amounting to $256 million to $260 million. **Labcorp Holdings (LH)** Labcorp Holdings provides various laboratory services, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid and hemoglobin tests among other quantitative analyses. Shares climbed to a 52-week high on Thursday of $325.58. In the second quarter, the company recorded a 5.8% increase, amounting to $3.73 billion in total revenues. The full year revenue for 2026 is estimated to reach $14.71 billion to $14.83 billion, reflecting a rise of 5.4% to 6.3%. Labcorp launched Marker, a new genetic testing platform last month, increasing consumer access to a personalized, hereditary health panel. The company also announced the availability of Roche's VENTANA PTEN test for prostate cancer in the U.S. to determine the viability of treatment with AstraZeneca's TRUQAP. **Hemab Therapeutics Holdings Inc. (COAG)** Hemab Therapeutics is a clinical-stage biotechnology company specializing in the development of therapies for blood coagulation disorders. Shares hit a 52-week high of $55.18 in intraday trading on Thursday. Net loss for Hemab nearly doubled in the second quarter at $24.2 million compared to $12.2 million in the previous year. Last month, the company reported positive data from the Phase 2 LTE trial assessing Sutacimig for treating Glanzmann thrombasthenia and Factor VIII deficiency. The results indicated that the mean annualized treated bleeding rate (ATBR) reduced by 84%, and the participants who underwent surgical procedures reported positive hemostatic outcomes. The company recently reported positive interim Phase 2 results for drug candidate HMB-002 in treating Von Willebrand's disease, and launched HMB-003, a new drug candidate for the treatment of heavy menstrual bleeding. **Aveanna Healthcare Holdings (AVAH)** Aveanna operates as a home care platform offering customized healthcare to medically complex and high-cost patient populations. Shares reached a 52-week high of $11.53 after rising over 24% on Thursday. As reported on Thursday, revenues rose 13.7% to $670.5 million in the second quarter of 2026. This resulted in a net income of $40 million, considerably higher than the $27 million in the previous year. Full year revenue for the fiscal year of 2026 are estimated to exceed $2.68 billion, compared to $2.43 billion in the fiscal year of 2025. **Candel Therapeutics Inc. (CADL)** Candel Therapeutics is a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients. On Thursday, the company's stock climbed over 10% to a 52-week high of $11.87. The company released second quarter financial results on Thursday, highlighting a considerably higher net loss of $38.90 million, compared to the previous year loss of $4.79 million, due to a change in the fair value of warrant liabilities. Candel's lead drug candidate is Aglatimagene besadenovec, which is being advanced for various cancer indications. The company expects to file a biologics license application (BLA) for the drug in treating prostate cancer by the fourth quarter of this year. The Phase 3 AURORA trial is also evaluating the drug in a combination therapy for non-small cell lung cancer (NSCLC). The company plans to advance Linoserpaturev in a Phase 2 study for recurrent glioblastoma (rGBM). **This Day In History:** On this day in 1910, Florence Nightingale passed away, leaving behind a legacy of pioneering antiseptic care in hospitals and clinical settings. The nursing specialist adopted a series of measures to decrease infection and mortality rates when assigned to a military hospital during the Crimean War. Her efforts to disinfect and maintain clean dressings for open wounds reduced mortality rates in the field medical unit by nearly 40%. Science historians also credit Nightingale with developing statistical methods to monitor and track patient illness. Ever the champion of modern, rigid nursing protocols, she once stated - "I am of certain convinced that the greatest heroes are those who do their duty in the daily grind of domestic affairs whilst the world whirls as a maddening dreidel." For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [PARK.US](https://longbridge.com/en/quote/PARK.US.md) - [AVAH.US](https://longbridge.com/en/quote/AVAH.US.md) - [COAG.US](https://longbridge.com/en/quote/COAG.US.md) - [LH.US](https://longbridge.com/en/quote/LH.US.md) - [CADL.US](https://longbridge.com/en/quote/CADL.US.md) ## Related News & Research - [Park Dental Partners (PARK) Stock Turns Profitable Again But Earnings Stay Uneven](https://longbridge.com/en/news/295983756.md) - [Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | CADL Stock News](https://longbridge.com/en/news/295797039.md) - [Aveanna Healthcare Q2 revenue beats on broad-based growth](https://longbridge.com/en/news/295788234.md) - [AVAH: Q2 2026 delivered double-digit revenue and net income growth, prompting raised full-year guidance](https://longbridge.com/en/news/295788801.md) - [Transcript: Park Dental Partners Q2 2026 Earnings Conference Call](https://longbridge.com/en/news/295806010.md)